showed that the moderately immunogenic CT26 colon cancer KRAS mutant showed activation signals in the tumor-draining lymph node as a biomarker of early response after ICI combination therapy of the same antibodies (anti-PD-1 and anti-CTLA-4) (39). This evidence concerns the gene CTLA4 and neoplasm.